N/A N=34 Assessing the Hemodynamic Benefits of Cardiac Resynchronization Therapy in Children Following Open-Heart Surgery
Congenital Heart Defects
Primary: Cardiac Index — 3.39; 3.42; 3.23 L/min/m2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=24 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit
Atrial Fibrillation
Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants
N/A N=15 An Assessment of Dual Site Left Ventricular Endocardial Pacing
Atrial Fibrillation · Ventricular Tachycardia · Heart Failure
Primary: Acute Haemodynamic Response to Dual Left Ventricular Pacing — 3.7 % difference — p=<0.05
N/A N=411 Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation
Heart Failure · Atrial Fibrillation
Primary: Composite of All-cause Mortality and Heart Failure Events — 50; 64 Participants
Phase 2 N=120 Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)
Left Ventricular Dysfunction
Primary: Global Left Ventricular Function — 3.5; 4.4; 2.8; 1.7 percentage of ejection fraction — p=0.959
N/A N=402 Heart Attack Prevention Programme for You (HAPPY) London
Cardiovascular Disease
Primary: Change in Pulse Wave Velocity (PWV) — -0.25; -0.16 m/s
Phase 2 N=87 Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)
Left Ventricular Dysfunction
Primary: Global Left Ventricular Function — 0.5; 3.6 percentage of ejection fraction — p=<0.05
N/A N=190 Attain Model 4196 Left Ventricular (LV) Lead
Heart Failure
Primary: Safety (Subjects Without a Model 4196 Lead Related Complication) — 168 participants
Phase 2 N=20 Pilot Study of Atorvastatin for Orthopedic Surgery Patients
Hip Fracture · Myocardial Ischemia · Inflammation
Primary: Percentage of All Enrolled Patients With a Peri-operative Rise in High-sensitivity Cardiac Troponin I — 20 percentage of patients
Phase 4 N=104 Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Heart Failure
Primary: Number of Participants Taking Ivabradine at 180 Days — 6; 21 Participants — p=0.002
Phase 3 N=48 EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes
Type 1 Diabetes
Primary: Change in Insulin Sensitivity — 12.2; -2.4 (mg/kg/min)/(insulin) — p=0.005
Phase 2 N=21 N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)
Transposition of Great Vessels · Congenital Heart Disease
Primary: Maximum Decline in Measured Cardiac Output — 0.68; 0.29 L/min/m2
N/A N=54 Diagnosis and Treatment of Sleep Apnea in the Acute Exacerbation of Heart Failure
Sleep Apnea · Heart Failure
Primary: Left Ventricular Ejection Fraction Improvement — 4.5; -.3 percent change
Phase 4 N=70 Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery?
Vitamin D Deficiency · Cardiomyopathies · Apoptosis
Primary: Caspase 2 Enzyme Level — 1.3; 2.0 cells/ HPF
Phase 2 N=28 Testosterone and Myocardial Perfusion in Coronary Heart Disease (CHD)
Coronary Heart Disease
Primary: Myocardial Perfusion — 1.83; 1.52 myocardial perfusion index